Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Impact of Bifidobacterium animalis subsp. lactis BLa80 and Lacticaseibacillus rhamnosus LRa05 supplementation on the gut microbiota and metabolic health of alcohol-consuming individuals: a randomised, double-blind, placebo-controlled trial.

  • 2025-06-16
  • Beneficial microbes 17(1)
    • Y Liu
    • J Wang
    • Y Gao
    • Z Wang
    • C Zhu
    • F Xu
    • Y Chen

Study Design

Type
Randomized Controlled Trial (RCT)
Sample size
n = 112
Population
112 healthy participants with alcohol-consuming habits
Methods
randomised, placebo-controlled trial, probiotic complex containing BLa80 and LRa05 (BLC) at 20 billion colony-forming units/day for eight weeks, gut microbiota via 16S rRNA gene sequencing, fecal SCFAs via GC-MS, metabolic indicators measured
Duration
eight weeks
Funding
Unclear
  • Large Human Trial
  • Rigorous Journal

Aim

this study explored the impact of BLa80 (Bifidobacterium animalis subsp. lactis) and LRa05 (Lacticaseibacillus rhamnosus) on the gut microbiota composition and metabolic indicators of volunteers with alcohol-consuming habits.

Methods

in this randomised, placebo-controlled trial, we assessed the impacts of a probiotic complex containing BLa80 and LRa05 (BLC) on the gut microbiota, short-chain fatty acids (SCFAs), alanine transaminase (ALT), aspartate aminotransferase (AST) and uric acid levels in healthy participants. A total of 112 subjects were randomly assigned to receive either a placebo (maltodextrin) or the intervention (maltodextrin + BLC at 20 billion colony-forming units/day) for eight weeks. Gut microbiota alterations were monitored via 16S rRNA gene sequencing, while fecal SCFAs were quantified via gas chromatography-mass spectrometry (GC-MS). Key metabolic indicators, including ALT, AST, and uric acid, were also measured.

Results

BLC intervention maintained the gut microbiota composition in participants with alcohol consumption habits, notably increasing the abundance of beneficial genera such as Blautia, Faecalibacterium, and Subdoligranulum. Significant alterations were observed in the levels of acetic acid, valeric acid, and total SCFAs, suggesting a favourable influence on gut health and metabolic function. Furthermore, BLC showed potential for improving serum uric acid levels.

Conclusion

supplementation with BLC appears to beneficially modulate the composition of the gut microbiota, aiding in the management of alcohol-related gastrointestinal disturbances and dependency. These findings highlight BLC's potential as a therapeutic adjunct for alcohol-induced gut dysbiosis, offering a non-pharmacological strategy to mitigate metabolic risks and improve gut barrier integrity in individuals with chronic alcohol consumption. This intervention may significantly contribute to gut health improvement.

Research Insights

Back to top